Results 191 to 200 of about 343,349 (228)

B7-H7 knockdown suppresses the proliferation, metastasis, and drug resistance of B-cell non-Hodgkin lymphoma cells by inhibiting the PI3K/Akt pathway. [PDF]

Front Oncol
Zhai A, Zou Q, Yin J, Ge S, Xiong X, Yan T, Xie X, Wang L.   +7 more
europepmc   +1 more source

GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts. [PDF]

Mol Ther Oncol
Okada R, Fanuzzi M, Rodriguez C, Oh J, Sreenivasan A, Stack HG, Puebla M, Phadke I, Cole AP, Bradford S, Kelly MC, Lei H, Ho M, Cotter JA, Thiele CJ, Zhang X, Nellan A, Nguyen R.   +17 more
europepmc   +1 more source

CD86(B7-'2)antigen on B cells from atopic patients shows selective, antigen-specific upregulation

CD86(B7-'2)antigen on B cells from atopic patients shows selective, antigen-specific upregulation
openaire  

CAR-T in relapsed refractory high-grade glioma and glioblastoma - who, what, when and how? [PDF]

Ecancermedicalscience
Parekh D, Patel AH, Khan A, Olojakpoke E, Karpe A, Peelay Z, Patil V.   +6 more
europepmc   +1 more source

Computational structural optimization enhances IL13Rα2 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape. [PDF]

Mol Ther
Meehl MM, Immadisetty K, Trivedi VD, Glowacki P, Prinzing B, Anido AA, Ibañez-Vega J, Leslie BJ, Babu MM, Krenciute G.   +9 more
europepmc   +1 more source

Single mutation tunes IRF4 function and mediates B cell character to ameliorate murine lupus. [PDF]

iScience
Xiao ZX, Liang R, Hu X, Huang C, Nie J, Xie C, Wang J, Fang Q, Fan X, Olsen N, Zhou L, Li B, Zheng SG.   +12 more
europepmc   +1 more source

Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy. [PDF]

Mol Cancer
Coelho RML, Debets R, Hammerl D.
europepmc   +1 more source

Immune checkpoint biology in hepatocellular carcinoma (Review). [PDF]

Oncol Lett
Hsieh CH, Chuang PC.
europepmc   +1 more source

B7-H3-mediated reversal of CAR-T cell exhaustion induces a notable antitumour response in ovarian cancer models. [PDF]

EBioMedicine
Liu Q, Deng M, Jiang J, Tang F, Chang X, Yang R, Liu P, Zhang Y, Wu D, Kong W, Ma Q, He J, Miao J.   +12 more
europepmc   +1 more source

High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years? [PDF]

J Immunother Cancer
Sondel PM, Rakhmilevich AL, Ansari IH, Erbe AK.   +3 more
europepmc   +1 more source